|
1
|
Mamelak AN and Jacoby DB: Targeted
delivery of antitumoral therapy to glioma and other malignancies
with synthetic chlorotoxin (TM-601). Expert Opin Drug Deliv.
4:175–186. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Goodenberger ML and Jenkins RB: Genetics
of adult glioma. Cancer Genet. 205:613–621. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Crocetti E, Trama A, Stiller C, Caldarella
A, Soffietti R, Jaal J, et al: RARECARE Working Group: Epidemiology
of glial and non-glial brain tumours in Europe. Eur J Cancer.
48:1532–1542. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Stupp R, Pavlidis N and Jelic S: ESMO
Guidelines Task Force: ESMO Minimum Clinical Recommendations for
diagnosis, treatment and follow-up of malignant glioma. Ann Oncol.
16:(Suppl 1). i64–i65. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Maher EA, Furnari FB, Bachoo RM, Rowitch
DH, Louis DN, Cavenee WK and DePinho RA: Malignant glioma: genetics
and biology of a grave matter. Genes Dev. 15:1311–1333. 2001.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Giese A, Rief MD, Loo MA and Berens ME:
Determinants of human astrocytoma migration. Cancer Res.
54:3897–3904. 1994.PubMed/NCBI
|
|
7
|
Louis DN, Pomeroy SL and Cairncross JG:
Focus on central nervous system neoplasia. Cancer Cell. 1:125–128.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Donato R, Sorci G, Riuzzi F, et al:
S100B's double life: intracellular regulator and extracellular
signal. Biochim Biophys Acta. 1793:1008–1022. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Chaves ML, Camozzato AL, Ferreira ED, et
al: Serum levels of S100B and NSE proteins in Alzheimer's disease
patients. J Neuroinflammation. 7:62010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sathe K, Maetzler W, Lang JD, et al: S100B
is increased in Parkinson's disease and ablation protects against
MPTP-induced toxicity through the RAGE and TNF-α pathway. Brain.
135:3336–3347. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Weide B, Richter S, Büttner P, et al:
Serum S100B, lactate dehydrogenase and brain metastasis are
prognostic factors in patients with distant melanoma metastasis and
systemic therapy. PLoS One. 8:e816242013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Lin J, Yang Q, Yan Z, Markowitz J, Wilder
PT, Carrier F and Weber DJ: Inhibiting S100B restores p53 levels in
primary malignant melanoma cancer cells. J Biol Chem.
279:34071–34077. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Rustandi RR, Baldisseri DM and Weber DJ:
Structure of the negative regulatory domain of p53 bound to
S100B(betabeta). Nat Struct Biol. 7:570–574. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Millward TA, Heizmann CW, Schäfer BW and
Hemmings BA: Calcium regulation of Ndr protein kinase mediated by
S100 calcium-binding proteins. EMBO J. 17:5913–5922. 1998.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Arcuri C, Bianchi R, Brozzi F and Donato
R: S100B increases proliferation in PC12 neuronal cells and reduces
their responsiveness to nerve growth factor via Akt activation. J
Biol Chem. 280:4402–4414. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Hartman KG, McKnight LE, Liriano MA and
Weber DJ: The evolution of S100B inhibitors for the treatment of
malignant melanoma. Future Med Chem. 5:97–109. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Smith J, Stewart BJ, Glaysher S, Peregrin
K, Knight LA, Weber DJ and Cree IA: The effect of pentamidine on
melanoma ex vivo. Anticancer Drugs. 21:181–185. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sibenaller ZA, Etame AB, Ali MM, Barua M,
Braun TA, Casavant TL and Ryken TC: Genetic characterization of
commonly used glioma cell lines in the rat animal model system.
Neurosurg Focus. 19:E12005. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Amberger VR, Hensel T, Ogata N and Schwab
ME: Spreading and migration of human glioma and rat C6 cells on
central nervous system myelin in vitro is correlated with tumor
malignancy and involves a metalloproteolytic activity. Cancer Res.
58:149–158. 1998.PubMed/NCBI
|
|
20
|
Gunnersen JM, Spirkoska V, Smith PE, Danks
RA and Tan SS: Growth and migration markers of rat C6 glioma cells
identified by serial analysis of gene expression. Glia. 32:146–154.
2000. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Grobben B, DE Deyn PP and Slegers H: Rat
C6 glioma as experimental model system for the study of
glioblastoma growth and invasion. Cell Tissue Res. 310:257–270.
2002. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Schlegel J, Piontek G, Kersting M,
Schuermann M, Kappler R, Scherthan H, et al: The p16/Cdkn2a/Ink4a
gene is frequently deleted in nitrosourea-induced rat glial tumors.
Pathobiology. 67:202–206. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Asai A, Miyagi Y, Hashimoto H, Lee SH,
Mishima K, Sugiyama A, et al: Modulation of tumor immunogenicity of
rat glioma cells by s-Myc expression: eradication of rat gliomas in
vivo. Cell Growth Differ. 11:1153–1158. 1994.
|
|
24
|
Mosmann T: Rapid colorimetric assay for
cellular growth and survival: application to proliferation and
cytotoxicity assays. J Immunol Methods. 65:55–63. 1983. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Bradford MM: A rapid and sensitive method
for the quantitation of microgram quantities of protein utilizing
the principle of protein-dye binding. Anal Biochem. 72:248–254.
1976. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Renault-Mihara F, Beuvon F, Iturrioz X,
Canton B, De Bouard S, Léonard N, et al: Phosphoprotein enriched in
astrocytes-15 kDa expression inhibits astrocyte migration by a
protein kinase C delta-dependent mechanism. Mol Biol Cell.
17:5141–5152. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Clarke J, Butowski N and Chang S: Recent
advances in therapy for glioblastoma. Arch Neurol. 67:279–283.
2010. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Rieger L, Weller M, Bornemann A, Schabet
M, Dichgans J and Meyermann R: BCL-2 family protein expression in
human malignant glioma: a clinical-pathological correlative study.
J Neurol Sci. 155:68–75. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Paul-Samojedny M, Kokocińska D, Samojedny
A, Mazurek U, Partyka R, Lorenz Z and Wilczok T: Expression of cell
survival/death genes: Bcl-2 and Bax at the rate of colon cancer
prognosis. Biochim Biophys Acta. 1741:25–29. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Pathak MK, Dhawan D, Lindner DJ, Borden
EC, Farver C and Yi T: Pentamidine is an inhibitor of PRL
phosphatases with anticancer activity. Mol Cancer Ther.
1:1255–1264. 2002.PubMed/NCBI
|
|
31
|
Zimmer DB, Lapidus RG and Weber DJ: In
vivo screening of S100B inhibitors for melanoma therapy. Methods
Mol Biol. 963:303–317. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Du R, Petritsch C, Lu K, Liu P, Haller A,
Ganss R, et al: Matrix metalloproteinase-2 regulates vascular
patterning and growth affecting tumor cell survival and invasion in
GBM. Neuro Oncol. 10:254–264. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Ding T, Zhou Y, Sun K, Jiang W, Li W, Liu
X, et al: Knockdown a water channel protein, aquaporin-4, induced
glioblastoma cell apoptosis. PLoS One. 8:e667512013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Verkman AS: Aquaporins in clinical
medicine. Annu Rev Med. 63:303–316. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Giese A: Glioma invasion-pattern of
dissemination by mechanisms of invasion and surgical intervention,
pattern of gene expression and its regulatory control by
tumorsuppressor p53 and proto-oncogene ETS-1. Acta Neurochir Suppl.
88:153–162. 2003.PubMed/NCBI
|
|
36
|
Sanderson L, Dogruel M, Rodgers J, et al:
Pentamidine movement across the murine blood-brain and
blood-cerebrospinal fluid barriers: effect of trypanosome
infection, combination therapy, P-glycoprotein, and multidrug
resistance-associated protein. J Pharmacol Exp Ther. 329:967–977.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Kotthaus J, Kotthaus J, Schade D, et al:
New prodrugs of the antiprotozoal drug pentamidine. ChemMedChem.
9:2233–2242. 2011. View Article : Google Scholar
|
|
38
|
Raseroka BH and Ormerod WE: The
trypanocidal effect of drugs in different parts of the brain. Trans
R Soc Trop Med Hyg. 80:634–641. 1986. View Article : Google Scholar : PubMed/NCBI
|
